Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8255378 | 0.86 | ACE2 (0.50) | CA5AANPEPMMP9MMP8ACE2 | |
| SCHEMBL5869378 | 0.86 | ACE2 (0.50) | CA5AANPEPMMP9MMP8ACE2 | |
| SCHEMBL8249276 | 0.78 | ACE2 (0.60) | CYP11B1CYP11B2ACE2 | |
| SCHEMBL1658524 | 0.78 | ACE2 (0.60) | CYP11B1CYP11B2ACE2 | |
| SCHEMBL8249249 | 0.75 | ACE2 (0.54) | CYP11B1CYP11B2ACE2 | |
| SCHEMBL7222066 | 0.75 | ACE2 (0.54) | CYP11B1CYP11B2ACE2 | |
| SCHEMBL5171581 | 0.73 | SLC7A5 (0.47) | CYP11B1CYP11B2 | |
| SCHEMBL22654375 | 0.73 | ACE2 (0.36) | CYP11B1CYP11B2ACE2 | |
| SCHEMBL7272523 | 0.72 | PIN1 (0.46) | CYP11B1CYP11B2ACE2 | |
| SCHEMBL3712781 | 0.72 | CYP11B1 (0.41) | CYP11B1CYP11B2MMP2MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | CA5A 1139/4885ANPEP 118/4885CYP11B1 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.